Bio Pharma Dive

OCTOBER 24, 2023

Rampart Biosciences closed a Series A round that will fund its goal to develop more potent DNA-based medicines that avoid immune responses.

DNA 275

DNA Medicine Immune Response Development 275

Bio Pharma Dive

JUNE 7, 2021

The identification of these novel clinical biomarkers allows researchers to better understand complex mechanisms of immune response to diseases, facilitating the development of more effective therapeutics.

Immune Response 276

Immune Response Development Research 276

Pharmaceutical Technology

AUGUST 1, 2022

GreenLight Biosciences has entered a partnership with the US National Institutes of Health (NIH) for the development of Covid-19 vaccines, which offer broader protection against new variants and with durable effects. They intend to develop vaccines that provide lasting immune responses compared to existing vaccines.

Vaccine 245

Vaccine Vaccination Development RNA 245

Pharmaceutical Technology

NOVEMBER 25, 2022

XtalPi has entered a strategic partnership with CK Life Sciences for artificial intelligence (AI)-driven tumour vaccine research and development (R&D). Under the collaboration, the companies will utilise their capabilities to co-develop a new AI tumour vaccine R&D platform.

Life Science 246

Life Science Vaccine Vaccination Development 246

Pharmaceutical Technology

NOVEMBER 16, 2022

Under the deal, the LentiPeak lentiviral vector technology platform and cell therapy production expertise of ElevateBio BaseCamp will be used by Affini-T to develop its investigational oncogenic driver programmes in the clinic. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Development 246

Development Gene Therapy Engineer Gene Editing 246

Pharmaceutical Technology

MARCH 20, 2023

RVAC Medicines has announced a research collaboration with the University of Pennsylvania (Penn) for the discovery and development of mRNA vaccines. The mRNA vaccine candidates will help reduce the chances of autoimmune responses that might lead to allergic conditions or serious autoimmune diseases.

Vaccine 245

Vaccine Vaccination Development Allergies 245

BioPharma Reporter

OCTOBER 11, 2022

Intranasal delivery of ChAdOx1 nCoV-19 failed to induce either a consistent mucosal antibody response or a strong systemic immune response, according to results from a Phase 1 clinical trial released today.

Immune Response 116

Immune Response Vaccine Vaccination Clinical Trials 116

Pharmaceutical Technology

DECEMBER 21, 2023

This innovative composition induces a protective immune response against Group A Streptococcus (GAS) bacteria, offering potential targets for vaccine development. Discover a groundbreaking immunogenic composition patent that combines GAS polypeptide antigens and polypeptide-polysaccharide conjugates.

Immune Response 100

Immune Response Bacteria Vaccine Vaccination 100

BioSpace

DECEMBER 10, 2020

The COVID-19 vaccine candidate developed by Sanofi and GlaxoSmithKline hit a snag that will delay the launch of a Phase III study due to an insufficient immune response in older trial patients.

Immune Response 95

Immune Response Vaccine Vaccination Trials 95

pharmaphorum

SEPTEMBER 7, 2020

A trial of Russia’s Sputnik V coronavirus vaccine has shown the jab produces an immune response, although the study was too small to produce conclusive findings, particularly on safety. But there are concerns that Russia has rushed development of the vaccine to claim a political victory in the race to get a vaccine approved.

Immune Response 107

Immune Response Vaccine Vaccination Trials 107

Medical Xpress

JANUARY 4, 2023

In a new study by researchers from Mass General Brigham's founding members, Brigham and Women's Hospital and Massachusetts General Hospital, a team extensively investigated the immune response of 16 adolescents and young adults who developed myocarditis after receipt of the COVID mRNA vaccine.

Immune Response 83

Immune Response Protein Vaccine Vaccination 83

STAT News

NOVEMBER 24, 2022

An experimental influenza vaccine developed using messenger RNA technology appears capable of inducing what should be a protective immune response against all known subtypes of flu, at least in animals. If the work is translated into humans it could turn out to be a version of a long-sought universal vaccine.

Vaccine 138

Vaccine Vaccination Development Immune Response 138

Pharmaceutical Technology

OCTOBER 6, 2022

BioLink Life Sciences has received a contract worth $750,000 from the US Biomedical Advanced Research and Development Authority (BARDA) to develop Ramatroban for treating Covid-19 pneumonia patients in the hospital setting.

Development 162

Development Life Science Immune Response Trials 162

Scienmag

JULY 12, 2021

Scientists have produced the first fine-detail molecular blueprints of a bacterial enzyme known as Lit, which is suspected to play a “stealthy” role in the progression of infection by reducing the immune response.

Immune Response 75

Immune Response Scientist Development Drugs 75

Pharma Mirror

NOVEMBER 30, 2020

Chippenham, UK: Vectura Group plc, an industry leading inhalation CDMO, today announces that it has signed a global out licence and development agreement with Kinaset Therapeutics Inc. for the development and commercialisation of VR588, a preclinical novel inhaled pan-JAK inhibitor for the prevention and treatment of severe asthma.

Development 130

Development Immune Response Clinical Trials Clinical Trials 130

Pharmaceutical Technology

OCTOBER 6, 2022

from the US National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) to develop a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG). Leveraging its outer membrane vesicles (OMV) platform technology, Intravacc will develop the vaccine.

Vaccine 147

Vaccine Vaccination Development Bacterium 147

Worldwide Clinical Trials

OCTOBER 14, 2024

Given the complexity and widespread impact of autoimmune and bone health conditions, developing new therapies is essential. For instance, drugs like belimumab, a monoclonal antibody, have shown promise in treating systemic lupus erythematosus and lupus nephritis by reducing the overactive immune response.

Research 147

Research Clinical Trials Clinical Trials Immune Response 147

Medical Xpress

APRIL 12, 2023

Testing the efficacy of a vaccine candidate is typically a long process, with the immune response of an animal model taking around two months.

Vaccine 118

Vaccine Vaccination Immune Response Development 118

Worldwide Clinical Trials

OCTOBER 14, 2024

Given the complexity and widespread impact of autoimmune and bone health conditions, developing new therapies is essential. For instance, drugs like belimumab, a monoclonal antibody, have shown promise in treating systemic lupus erythematosus and lupus nephritis by reducing the overactive immune response.

Research 130

Research Clinical Trials Clinical Trials Immune Response 130

Pharmaceutical Technology

MAY 22, 2023

It can suppress Th2 immune responses by binding to IL-17RB on Type 2 innate lymphoid cells (ILC2s). This blocks a cascade of responses that are induced by interleukin-25 (IL-25), a critical cytokine which is classified as ‘alarmin’. “As

Immune Response 273

Immune Response Clinical Trials Clinical Trials Antibody 273

Scienmag

APRIL 16, 2021

Credit: (C) Erica Tandori Researchers within the Biomedicine Discovery Institute at Monash University have made a breakthrough in understanding the role played by high-risk immune genes associated with the development of rheumatoid arthritis (RA).

Immune Response 97

Immune Response Gene Research Development 97

Pharma Times

MARCH 24, 2022

Collaboration will focus on AI analysis of flu progression, immune responses and the development of new vaccines

Immune Response 142

Immune Response Vaccine Vaccination Development 142

Camargo

DECEMBER 13, 2021

The development of biological products (or biologics) represents a major advancement in modern medicine, enabling the treatment of patients with many illnesses where no other therapeutics were previously available. One common characteristic for most if not all biologics is the triggering of an immune response or anti-drug antibodies.

Development 161

Development Production Immune Response Licensing 161

Pharmaceutical Technology

APRIL 5, 2023

Absci has collaborated with bioinformatics firm M2GEN to expedite the development of new cancer medicines. Absci stated that this collaboration combines AI drug creation technology and oncology bioinformatics, thereby reducing the time and cost of cancer drug development.

Development 130

Development Bioinformatics Drugs Immune Response 130

Pharmaceutical Technology

DECEMBER 6, 2022

Evaxion Biotech and ExpreS 2 ion Biotechnologies have entered a vaccine discovery collaboration agreement to co-develop a new cytomegalovirus (CMV) vaccine candidate. Additionally, this project will be part of the development pipeline of Evaxion under EVX-V1. Evaluations will follow this method in preclinical models of Evaxion.

Vaccine 130

Vaccine Vaccination Development Immune Response 130

Pharmaceutical Technology

MAY 12, 2023

Absci has collaborated with the University of Oxford’s Kennedy Institute of Rheumatology to expedite the development of AI-driven immunotherapies. The company will then reassemble the antigen-antibody pairs, using its reverse immunology approach, as starting points for the development of drugs.

Development 130

Development Antibody Immune Response Genomics 130

Pharmaceutical Technology

APRIL 28, 2023

Biotechnology company Therini Bio has raised $36m in a Series A financing round to develop fibrin-targeted therapies to treat neurodegenerative and retinal diseases. THN391 binds the inflammation-driving component of fibrin, known for activating the immune responses in neurodegenerative and ophthalmologic diseases.

Development 130

Development Immune Response Clinical Trials Clinical Trials 130

BioSpace

AUGUST 13, 2020

A COVID-19 vaccine candidate developed by Chinese pharmaceutical company Sinopharm triggered antibody-based immune responses in early and mid-stage trials.

Immune Response 132

Immune Response Vaccine Vaccination Antibody 132

BioPharma Reporter

DECEMBER 11, 2020

Sanofi and GSK announced a delay on Friday in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly, saying clinical trials showed an insufficient immune response in older people.

Immune Response 105

Immune Response Vaccine Vaccination Trials 105

BioPharma Reporter

JANUARY 25, 2021

Merck is shutting down the programs linked to its two COVID-19 vaccine candidates following early trial data indicating that they failed to generate immune responses comparable to a natural infection or existing vaccines.

Vaccine 98

Vaccine Vaccination Immune Response Development 98

Pharmaceutical Technology

FEBRUARY 13, 2023

According to the GlobalData Pharma Intelligence Center, there are currently 71 PROTACs in development in the oncology pipeline by non-academic developers, mostly clustering in the preclinical and discovery phases, with only 14 agents in clinical stages.

Development 147

Development Protein Immune Response Trials 147

Pharmaceutical Technology

FEBRUARY 6, 2023

Led by Feinstein Institutes researcher Haichao Wang, the new study focuses on detecting protein mediators that might contribute to uncontrolled immune responses to lethal infections. Researchers at the Feinstein Institutes for Medical Research have discovered a new protein that can be a potential therapeutic target for lethal sepsis.

Protein 263

Protein Research Antibody Immune Response 263

Pharmaceutical Technology

NOVEMBER 11, 2022

The latest development comes after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) provided a positive opinion on vaccine use. The vaccine elicited a robust immune response against several variants in registrational trials conducted when the Omicron variant of the virus was dominant.

Vaccine 246

Vaccine Vaccination Immune Response Protein 246

Pharmaceutical Technology

MAY 25, 2023

A new vaccine developed by the Serum Institute of India to fight meningococcal disease could help eliminate meningitis across Africa. The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. for serogroup W to 20.5

Vaccine 195

Vaccine Vaccination Immune Response Bacteria 195

Drug Patent Watch

DECEMBER 9, 2024

The Role of Analytical Characterization Analytical characterization is a critical step in the development of biosimilars. Additionally, the immunogenicity of biosimilars, which is the ability of the drug to trigger an immune response, can be highly variable and impact the safety and efficacy of the drug. References Bilea, A.

Clinical Trials 97

Clinical Trials Clinical Trials Immune Response Production 97

BioSpace

DECEMBER 2, 2021

IDRI is working with a newly-formed consortium to develop a next-gen COVID-19 vaccine that will be stable at routine temperatures and that may be able to confer immunity for a longer duration.

Immune Response 76

Immune Response Vaccine Vaccination Development 76

Pharmaceutical Technology

FEBRUARY 15, 2023

New generation of monoclonal antibodies (bi-specific antibodies) are considered active immunotherapies because they link immune cells and cancer cells to activate anti-cancer immune response. Immatics undertakes the discovery of targets for cancer immunotherapies with the development of the right T-cell receptors.

Antibody 261

Antibody Immune Response Protein Development 261